Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 0.58 |
| ▸ | PLG | P00747 | 13/20 | 0.56 |
| ▸ | PLAT | P00750 | 11/20 | 0.56 |
| ▸ | KLK1 | P06870 | 11/20 | 0.56 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779408 | 0.86 | PLAU (0.52) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5776635 | 0.84 | PLAU (0.53) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5776002 | 0.80 | PLAU (0.65) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5777574 | 0.79 | SLC6A4 (0.46) | PLAUPLGPLATKLK1 | |
| SCHEMBL6969881 | 0.75 | PLAU (0.52) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5777466 | 0.74 | PLAU (0.73) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5771959 | 0.74 | PLAU (1.00) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5775814 | 0.71 | PLAU (1.00) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL29531162 | 0.71 | PLAU (1.00) | PLAUPLGPLATKLK1F2 | |
| SCHEMBL5773262 | 0.71 | PLAU (0.64) | PLAUPLGPLATKLK1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | claimed |
| US-6495562-B1 | SUCH AS 6-(2-(4,4-DIETHYL-1-ISOPROPYL-3,4-DIHYDRO-6-ISOQUINOLINYL)CYCLOPROPYL)-2 -NAPHTHALENECARBOXIMIDAMIDE | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | claimed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| EP-1276722-B1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6504031-B1 | Enzyme inhibitor such as 6-(2-(1-isopropyl-1,2,3,4-tetrahydro -7-isoquinolinyl)ethenyl)-2-naphthalenecarboximidamide, used as angiogenesis inhibitors; antiarthritic, antiinflammatory and antitumor agents | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| US-6495562-B1 | SUCH AS 6-(2-(4,4-DIETHYL-1-ISOPROPYL-3,4-DIHYDRO-6-ISOQUINOLINYL)CYCLOPROPYL)-2 -NAPHTHALENECARBOXIMIDAMIDE | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |